Decades of research from Johns Hopkins, Imperial College, and others show that psilocybin has one of the lowest risk profiles of any psychoactive compound when used in supported settings. Learn how Oregon’s licensed model translates this science into practice—through screening, trained facilitators, lab-tested products, and integration—to ensure participant safety and peace of mind.

While solo journeys can be profound, there’s another way to work with psilocybin that taps into something just as ancient and vital: togetherness.

Across cultures and throughout history, psychedelics have been used not only for individual healing but for community connection. In today’s legal psilocybin spaces, we’re beginning to remember this. Whether in pairs or in circles, psilocybin can help us peel back the layers of separation and remember that connection is medicine, too.

As psilocybin-assisted healing becomes more accessible, one question comes up again and again: Can I take psilocybin if I’m on antidepressants like SSRIs? The short answer is: yes, you can. But it may affect how psilocybin works—and it may also raise deeper questions about what kind of healing you’re after.

In this post, we’ll explore how SSRIs and psilocybin interact, what the research says, and why some people are beginning to explore psychedelics as an alternative to long-term pharmaceutical treatment.

What if the next creative breakthrough doesn’t come from pushing harder—but from softening into presence, where inspiration can find you again?

In recent years, more artists, entrepreneurs, and everyday makers are turning to psilocybin, the active compound in “magic” mushrooms, not for escape—but for reconnection. Whether through microdosing or intentional journeys, this ancient medicine is helping people access something many of us have lost in the grind: our creative spark.

Let’s be real, psychedelics have a complicated reputation. For some, the word still conjures images of tie-dye and “bad trips.” For others, it's synonymous with personal healing, insight, and transformation. So let’s pause and ask: Where did the stigma come from? What does the science actually say now? And how do we create more informed, grounded conversations, especially as access continues to grow?

Psilocybin and other psychedelics are emerging as powerful tools in easing the emotional, spiritual, and existential distress that often accompanies terminal illness and cancer. With clinical research and compassionate care guiding the way, psychedelic-assisted support is helping many people find peace at the edge of life.

In the last few years, there’s been a quiet but powerful shift in how the medical world views psilocybin—the active compound found in certain psychedelic mushrooms. Once misunderstood or stigmatized, this naturally occurring substance is now being recognized for its potential to support healing, especially in people living with depression. In fact, the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to multiple psilocybin-based treatments. But what does that actually mean? And why does it matter?

This article explores a new Nature study on psilocybin's unique impact on brain connectivity. Unlike traditional antidepressants, psilocybin appears to increase global neural communication, offering insights into its long-term therapeutic potential. A must-read for anyone interested in the neuroscience behind psychedelic-assisted support.